WO2010053335A2 - 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에 의해 제조된 분말 및 이를 포함하는 약학적 조성물 - Google Patents

난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에 의해 제조된 분말 및 이를 포함하는 약학적 조성물 Download PDF

Info

Publication number
WO2010053335A2
WO2010053335A2 PCT/KR2009/006585 KR2009006585W WO2010053335A2 WO 2010053335 A2 WO2010053335 A2 WO 2010053335A2 KR 2009006585 W KR2009006585 W KR 2009006585W WO 2010053335 A2 WO2010053335 A2 WO 2010053335A2
Authority
WO
WIPO (PCT)
Prior art keywords
insoluble drug
powder
nanoparticles
pharmaceutical composition
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/006585
Other languages
English (en)
French (fr)
Other versions
WO2010053335A3 (ko
Inventor
배준호
이혁
홍덕기
이종휘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Priority to US13/127,957 priority Critical patent/US20110212169A1/en
Priority to CN2009801511834A priority patent/CN102256597A/zh
Publication of WO2010053335A2 publication Critical patent/WO2010053335A2/ko
Publication of WO2010053335A3 publication Critical patent/WO2010053335A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에 의해 제조된 분말 및 이를 포함하는 약학적 조성물에 관한 것이다. 본 발명의 제조방법 은 표면 안정화제의 존재 하에 나노입자화된 난용성 약물의 균질화된 분산 용액을 제공하는 단계, 균질화된 분산 용액과 수용성 분산제 용액을 혼합하는 단계, 및 결 과로서 얻어진 혼합 용액을 건조시켜 분말을 회수하는 단계를 포함한다. 본 발명의 제조방법에 의한 난용성 약물의 나노입자를 포함하는 분말은 수용 액에 재분산시 난용성 약물이 나노수준의 입자크기를 유지하면서,약물의 용해도와 용출속도가 증가하여 향상된 생체이용률을 나타내므로, 난용성 약물의 경구 투여 또는 비경구 투여를 목적으로 하는 제형 개발에 유용하게 활용될 수 있다.
PCT/KR2009/006585 2008-11-10 2009-11-10 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에 의해 제조된 분말 및 이를 포함하는 약학적 조성물 Ceased WO2010053335A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/127,957 US20110212169A1 (en) 2008-11-10 2009-11-10 METHOD FOR PRODUCING POWDER CONTAINING NANOPARTICULATED SPARINGLY SOLUBLE DRUG, POWDER PRODUCED THEREBY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME (As Amended)
CN2009801511834A CN102256597A (zh) 2008-11-10 2009-11-10 制备含有不溶性药物的纳米颗粒的粉末的方法、由此制备的粉末以及含有该粉末的药物组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0111205 2008-11-10
KR1020080111205A KR20100052262A (ko) 2008-11-10 2008-11-10 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에의해 제조된 분말 및 이를 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2010053335A2 true WO2010053335A2 (ko) 2010-05-14
WO2010053335A3 WO2010053335A3 (ko) 2010-09-10

Family

ID=42153421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006585 Ceased WO2010053335A2 (ko) 2008-11-10 2009-11-10 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에 의해 제조된 분말 및 이를 포함하는 약학적 조성물

Country Status (4)

Country Link
US (1) US20110212169A1 (ko)
KR (1) KR20100052262A (ko)
CN (1) CN102256597A (ko)
WO (1) WO2010053335A2 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102048702A (zh) * 2010-12-03 2011-05-11 山东大学 一种联苯双酯纳米结晶制剂及其制备方法
CN102342912A (zh) * 2010-08-02 2012-02-08 中国科学院上海药物研究所 坎地沙坦酯纳米乳及其制备方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
HUP0900384A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
KR101218428B1 (ko) * 2010-08-26 2013-01-03 영남대학교 산학협력단 막유화법을 이용한 실리마린 경구용 고형제제 조성물 및 그 제조방법
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
CN103284952A (zh) * 2012-02-29 2013-09-11 北京万生药业有限责任公司 一种含有非诺贝特的药物组合物
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CA2882730C (en) 2012-08-22 2019-12-31 Arbor Pharmaceuticals, Llc Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CN102895185B (zh) * 2012-11-05 2015-03-25 西安德天药业股份有限公司 一种联苯双酯速释微丸及其制备方法和应用
CN102920654B (zh) * 2012-11-14 2014-04-23 沈阳药科大学 缬沙坦喷雾干燥纳米混悬剂及其制备方法
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
CN103705494A (zh) * 2013-12-26 2014-04-09 湖北医药学院 一种胰岛素纳米透皮贴剂及其制备方法
CN103655501A (zh) * 2013-12-26 2014-03-26 湖北医药学院 一种纳米布洛芬干粉与片剂及其制备方法
KR101576587B1 (ko) * 2014-02-05 2015-12-10 한양대학교 에리카산학협력단 신규한 페노피브레이트 함유 젤라틴 나노입자
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
CN104606139B (zh) * 2014-05-16 2018-01-09 沈阳药科大学 一种药物粉末的制备与应用
CA2980170A1 (en) 2015-03-19 2016-09-22 Cydex Pharmaceuticals, Inc. Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
US11147811B2 (en) 2016-03-10 2021-10-19 Sumitomo Dainippon Pharma Co., Ltd. Composition comprising fine particle and process thereof
CN107441048A (zh) * 2016-05-31 2017-12-08 深圳信立泰药业股份有限公司 一种阿利沙坦酯药物组合物及含有该药物组合物的制剂及其制备方法
CN106361695B (zh) * 2016-08-26 2017-12-19 湖北唯森制药有限公司 一种右旋布洛芬的研磨方法及其混悬液的制备方法
EP3960158B1 (en) 2016-10-07 2025-05-21 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
WO2019200143A1 (en) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
CN108815149A (zh) * 2018-09-04 2018-11-16 广州君博医药科技有限公司 一种非甾体抗炎眼膏及其制备方法
CN109394716A (zh) * 2019-01-07 2019-03-01 安徽东盛友邦制药有限公司 一种新型纳米布洛芬片剂及其制备方法
CN109481419B (zh) * 2019-01-16 2021-04-02 中国人民解放军陆军军医大学第一附属医院 一种罗格列酮纳米制剂及其制备方法和用途
CN110478316A (zh) * 2019-02-27 2019-11-22 江西中医药大学 一种阿瑞吡坦纳米结晶混悬剂及其制备方法和应用
KR20200106607A (ko) * 2019-03-05 2020-09-15 주식회사 코아팜바이오 오셀타미비르 함유 의약 조성물
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
CN112451520B (zh) * 2020-12-31 2021-10-15 江苏宇锐医药科技有限公司 一种缬沙坦氨氯地平组合物及其制备方法
AU2022368370B2 (en) * 2022-03-08 2025-02-20 Cnpharm Co., Ltd. Pharmaceutical composition containing docetaxel or pharmaceutically acceptable salt thereof and preparation method therefor
CN114886856A (zh) * 2022-06-09 2022-08-12 山西辅仁恒峰药业有限公司 一种奥司他韦纳米干混悬剂的制备方法及应用
KR20250052834A (ko) * 2023-10-12 2025-04-21 주식회사 다산제약 프란루카스트의 생체이용률이 개선된 약제학적 조성물 및 그 제조방법
KR102756809B1 (ko) * 2023-10-13 2025-01-22 표재성 난용성 진세노사이드의 수용해도를 높인 조성물, 이를 이용한 화장품조성물 및 건강기능식품

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6437050B1 (en) * 2001-10-04 2002-08-20 Bridgestone Corporation Nano-particle preparation and applications
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
KR100623013B1 (ko) * 2004-09-04 2006-09-19 김영대 나노에멀션, 그의 용도 및 제조방법
US20070224259A1 (en) * 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102342912A (zh) * 2010-08-02 2012-02-08 中国科学院上海药物研究所 坎地沙坦酯纳米乳及其制备方法
CN102048702A (zh) * 2010-12-03 2011-05-11 山东大学 一种联苯双酯纳米结晶制剂及其制备方法

Also Published As

Publication number Publication date
CN102256597A (zh) 2011-11-23
US20110212169A1 (en) 2011-09-01
WO2010053335A3 (ko) 2010-09-10
KR20100052262A (ko) 2010-05-19

Similar Documents

Publication Publication Date Title
WO2010053335A2 (ko) 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에 의해 제조된 분말 및 이를 포함하는 약학적 조성물
EP1886673A3 (en) Solid dosage form of enteric solid dispersion and method for producing the same
CN104273522B (zh) 一种姜黄素纳米复合物及其制备方法
PH12015501782A1 (en) Method for production of commercial nanoparticles and microparticle powders
WO2012051426A3 (en) Aggregate nanoparticulate medicament formulations, manufacture and use thereof
PT1765294E (pt) Microesferas de ácido nucleico, sua produção e entrega
MX2011013726A (es) Nanodispersión de un medicamento y proceso para su preparación.
WO2007109457A3 (en) Stable concentrated metal colloids and methods of making same
CN110198742A (zh) 一种纳米炭-铁复合体系及其组合物、制备方法和用途
JP2014114280A (ja) 印刷に適した錠剤の製造法
GB2469965A (en) Nanoparticle carriers for drug administration and process for producing same
EP1886672A3 (en) Solid dosage form comprising solid dispersion and method for producing the same
WO2009007992A3 (en) Pharmaceutical composition produced by microprecipitation
WO2011034394A3 (ko) 옥살리플라틴의 나노 입자 및 이를 제조하는 방법
TW200740697A (en) Yttrium oxide composition, method of preparing the same, and method of forming yttrium oxide layer using the same
CN103316349B (zh) 一种油混悬剂稳定剂、兽用油混悬剂及其制备方法
CN106924228B (zh) 一种姜黄素组合物及其制备方法和应用
WO2008084823A1 (ja) 褐色皮膜組成物およびその調製方法
WO2005063210A3 (en) Loading of a camptothecin drug into colloidal nanoparticles
Wu et al. Fluorescent realgar quantum dots: new life for an old drug
WO2008026224A3 (en) Novel nanoparticles of apotransferrin / transferrin, pharmaceutical composition containing them and processes for their preparation
WO2017024953A1 (zh) 尼莫地平水溶性衍生物及其制备方法和应用
CN103948593B (zh) 阿维莫泮药物组合物及其制备方法
Jia Towards sustainable preparation of oral solid dosage form of drug nanoparticles
CN103934463A (zh) 一步法合成功能化纳米金粒子溶胶

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980151183.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09825018

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13127957

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09825018

Country of ref document: EP

Kind code of ref document: A2